Compare Atomera Incorporated (ATOM) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Atomera Incorporated vs State Street SPDR S&P Biotech ETF — how do they compare? Atomera Incorporated trades at $6.2 (market cap $247.40M), while State Street SPDR S&P Biotech ETF trades at $156. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Atomera Incorporated nearer its low. Which is the better fit depends on your goals.
| ATOM | XBI | |
|---|---|---|
Market Cap | $247.40M | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $12.11 | $164.28 |
52-Week Low | $1.99 | $85.16 |
Enterprise Value | $207.61M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ATOM trades at $6.25, down 5.73% over 24 hours, reflecting a bearish technical outlook with negative earnings trends. The company reported a net loss of $20.17 million in 2025 on minimal revenue of $65,000, with profitability metrics deeply negative. Recent news highlights Atomera's focus on semiconductor technology advancements, including GaN-on-Silicon collaborations, but financial performance remains a significant concern.
The outlook is cautious due to persistent losses and weak revenue, though analyst consensus is unanimously bullish with a 100% buy rating. Key risks include execution challenges in monetizing technology and high cash burn. Upside depends on successful commercialization of its semiconductor IP, but current fundamentals suggest high volatility and substantial shareholder risk.
XBI trades at $155.34, down 2.32% on the day, but maintains a bullish technical outlook with strong momentum indicators. The biotech ETF has gained significant attention after a 17% monthly surge, driven by sector rotation and M&A activity. Analyst coverage remains limited with a single hold rating, though recent news highlights biotech's strong performance amid market volatility.
The ETF offers exposure to biotech's resurgence with AI drug discovery and deal momentum as catalysts. However, high volatility and concentrated sector risk require careful position sizing. Current technical strength suggests potential for continued upside if sector momentum persists.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Atomera Incorporated
Atomera is a semiconductor materials engineering company. Its Mears Silicon Technology (MST) is a patented thin film that enhances transistor performance, power efficiency, and cost for global chip manufacturers.
Read more on ATOM →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
